Court Appoints KSF as Lead Counsel in Orexigen Securities Fraud Class Action

On June 22, 2015, the United States District Court for the Southern District of California appointed KSF as sole lead counsel in In re Orexigen Therapeutics, Inc., Securities Litigation, 15cv540 L (KSC), stating,”[t]he Court has reviewed the firm’s resume, See Abadou Decl., Exh. D, ECF No. 37-6, and is satisfied that the lead plaintiff has made a reasonable choice of counsel. The Kahn Swick & Foti firm has extensive experience in the prosecution of securities class actions and it appears that it will adequately represent the interests of all class members.”